Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brent L Wood

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 14, 2013
Flow cytometric monitoring of residual disease in acute leukemiaBrent L Wood
Current Protocols in Cytometry|April 21, 2020
Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal ApproachBrent L Wood
Cytometry. Part B, Clinical Cytometry|April 25, 2015
Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometryBrent L Wood
Current Protocols in Cytometry|September 5, 2008
Ten-color immunophenotyping of hematopoietic cellsBrent L Wood
Clinics in Laboratory Medicine|July 31, 2007
Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemiaBrent L Wood
Cytometry. Part B, Clinical Cytometry|April 22, 2009
Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphomaKristin Mantei, Brent L Wood
Current Hematologic Malignancy Reports|November 4, 2017
Methods of Detection of Measurable Residual Disease in AMLYi Zhou, Brent L Wood
Blood Reviews|October 16, 2016
Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexitiesXueyan Chen, Brent L Wood
Best Practice & Research. Clinical Haematology|October 21, 2017
How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?Xueyan Chen, Brent L Wood
Seminars in Diagnostic Pathology|November 12, 2023
Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysisAlexandra E Kovach, Brent L Wood
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Methods in Molecular Biology (Clifton, N.J.)|May 14, 2013
Flow cytometric monitoring of residual disease in acute leukemiaBrent L Wood
Current Protocols in Cytometry|April 21, 2020
Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal ApproachBrent L Wood
Cytometry. Part B, Clinical Cytometry|April 25, 2015
Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometryBrent L Wood
Current Protocols in Cytometry|September 5, 2008
Ten-color immunophenotyping of hematopoietic cellsBrent L Wood
Clinics in Laboratory Medicine|July 31, 2007
Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemiaBrent L Wood
Cytometry. Part B, Clinical Cytometry|April 22, 2009
Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphomaKristin Mantei, Brent L Wood
Current Hematologic Malignancy Reports|November 4, 2017
Methods of Detection of Measurable Residual Disease in AMLYi Zhou, Brent L Wood
Blood Reviews|October 16, 2016
Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexitiesXueyan Chen, Brent L Wood
Best Practice & Research. Clinical Haematology|October 21, 2017
How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?Xueyan Chen, Brent L Wood
Seminars in Diagnostic Pathology|November 12, 2023
Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysisAlexandra E Kovach, Brent L Wood
Pageof 18